Clinical Value Discussion of Nimotuzumab Combined with Radiotherapy and Chemotherapy in Treatment of Cervical Cancer
Objective To study the clinical value of nimotuzumab and chemoradiotherapy in cervical cancer.Methods 80 cervical cancer patients admitted to our hospital in 2022 were selected as the study subjects and randomly divided into control group and study group,with 40 patients in each group.The control group adopted concurrent chemoradiotherapy,and the study group combined nytuzumab on the basis of the control group,and compared the treatment effects of different methods.Results After treatment,the treatment response rate was higher than the control group(P<0.05);the study group B7-H4,PCNA,HIF-1 ɑ was lower than the control group;FH 1 T,PTEN,and STC 1 were higher than the control group(P<0.05);the study group had high probability of toxicity and side effects,but P>0.05.Conclusion The use of concurrent radiotherapy and chemotherapy combined with nimotuzumab to treat cervical cancer can improve the mRNA expression of proliferation genes of focal cancer cells,and the safety of treatment is high.This scheme is suggested to be applied.
NimotuzumabRadiochemotherapyCervical cancerCurative effectToxic side effect
NETL
NSTL
万方数据
